OpenNashEarnings

Health Care · NYSE: DOCS

Doximity earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends March · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q2 FY2027

Doximity paired its new DoseCheck medication-safety verifier with UpToDate content in its clinical AI as more than 190 health systems bought the AI suite and pharma began buying AI search.

Doximity launched DoseCheck, a deterministic verifier that checks AI drug-dose answers against its own drug dataset, and added UpToDate to its AI answers. More than 190 health systems now buy its AI suite, including New York Presbyterian, which offers it inside its electronic health record. A new patient context feature lets doctors ask chart-specific questions. On the pharma side, 16 of the top 20 companies have bought AI search, a product that places advertising inside AI answers.

Read the Q2 FY2027 summary →

Quarters

KPI history

Revenue$174.5M+3.6% y/yQ2 FY27
Q3 FY25: $168.6MQ3 25$168.6MQ4 FY25: $138.3M (worked out from the annual figure)Q4 25$138.3MQ1 FY26: $145.9MQ1 26$145.9MQ2 FY26: $168.5MQ2 26$168.5MQ3 FY26: $185.1MQ3 26$185.1MQ4 FY26: $145.4M (worked out from the annual figure)Q4 26$145.4MQ1 FY27: $156.6MQ1 27$156.6MQ2 FY27: $174.5MQ2 27$174.5M

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$168.6M
Q4 FY25$138.3M *
Q1 FY26$145.9M
Q2 FY26$168.5M
Q3 FY26$185.1M
Q4 FY26$145.4M *
Q1 FY27$156.6M
Q2 FY27$174.5M
Diluted EPS (GAAP)$0.18−41.9% y/yQ2 FY27
Q3 FY25: $0.37Q3 25$0.37Q1 FY26: $0.27Q1 26$0.27Q2 FY26: $0.31Q2 26$0.31Q3 FY26: $0.31Q3 26$0.31Q1 FY27: $0.13Q1 27$0.13Q2 FY27: $0.18Q2 27$0.18
Data
Q3 FY25$0.37
Q1 FY26$0.27
Q2 FY26$0.31
Q3 FY26$0.31
Q1 FY27$0.13
Q2 FY27$0.18

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin25.2%−12.6 pts y/yQ2 FY27
Q3 FY25: 47.4%Q3 2547.4%Q4 FY25: 35.2%Q4 2535.2%Q1 FY26: 37.4%Q1 2637.4%Q2 FY26: 37.8%Q2 2637.8%Q3 FY26: 38.9%Q3 2638.9%Q4 FY26: 17.1%Q4 2617.1%Q1 FY27: 21.5%Q1 2721.5%Q2 FY27: 25.2%Q2 2725.2%
Data
Q3 FY2547.4%
Q4 FY2535.2%
Q1 FY2637.4%
Q2 FY2637.8%
Q3 FY2638.9%
Q4 FY2617.1%
Q1 FY2721.5%
Q2 FY2725.2%
Free cash flow$93.3M−0.7% y/yQ2 FY27
Q3 FY25: $65.2MQ3 25$65.2MQ4 FY25: $98.5MQ4 25$98.5MQ1 FY26: $62.1MQ1 26$62.1MQ2 FY26: $93.9MQ2 26$93.9MQ1 FY27: $41.9MQ1 27$41.9MQ2 FY27: $93.3MQ2 27$93.3M
Data
Q3 FY25$65.2M
Q4 FY25$98.5M
Q1 FY26$62.1M
Q2 FY26$93.9M
Q1 FY27$41.9M
Q2 FY27$93.3M

Operating cash flow minus capital expenditure, from cash flow statements.

Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue$168.6M$138.3Md$145.9M$168.5M$185.1M$145.4Md$156.6M$174.5M
Gross margin91.6%89.5%89.2%90.3%89.9%86.7%84.9%85.5%
Operating income$79.9M$48.7Md$54.5M$63.7M$71.9M$24.8Md$33.6M$43.9M
Operating margin47.4%35.2%37.4%37.8%38.9%17.1%21.5%25.2%
Net income$75.2M$62.5Md$53.3M$62.1M$61.6M$19.1Md$24.3M$34.7M
Diluted EPS$0.37—$0.27$0.31$0.31—$0.13$0.18
Operating cash flow$65.2Md$98.5Md$62.1M$93.9Md$60.9Md$109.5Md$42.0M$93.3Md
Capital expenditure$0.00d$0.00d$0.00$0.00d——$62.0K$0.00d
Free cash flow$65.2M$98.5M$62.1M$93.9M——$41.9M$93.3M
R&D expense$22.4M$24.8Md$26.8M$30.2M$34.6M$39.1Md$38.5M$42.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings